CD68 and metastatic malignant neoplasm: In the aforementioned study by Richardsen et al. [12], higher percentages of CD68+ cells were seen in the epithelial and stromal primary-tumor compartments of non-metastatic cancers compared to metastatic cancers (48% vs. 28%, p = 0.029 in the epithelial compartment; 54% vs. 14%, p = 0.008 in the stromal compartment, respectively) (n = 59).